Fang Mel

Title: Fang Mel: Innovator in Cancer Research

Introduction

Fang Mel is a prominent inventor based in League City, TX (US). She has made significant contributions to the field of cancer research, particularly in understanding the role of tumor susceptibility gene 101 (TSG 101) in ovarian cancer. Her work has the potential to impact diagnostic and therapeutic approaches in oncology.

Latest Patents

Fang Mel holds a patent for the invention titled "Use of tumor susceptibility gene 101 (TSG 101) as a prognostic and diagnostic marker." This patent discloses the link between oncogenic Ras and TSG101, highlighting the negative effect of TSG101 on the expression of p21 in ovarian cancer. The invention also emphasizes the use of TSG101 as a prognostic and diagnostic marker, as well as a potential therapeutic target in cancer, especially ovarian cancer.

Career Highlights

Fang Mel is affiliated with the University of Texas System, where she continues her research and innovation in cancer diagnostics and therapeutics. Her work is recognized for its potential to improve patient outcomes in ovarian cancer treatment.

Collaborations

Fang Mel collaborates with notable colleagues, including Xiaodong Cheng and Travis Young, to advance research in her field. Their combined expertise contributes to the development of innovative solutions in cancer research.

Conclusion

Fang Mel's contributions to cancer research through her patent on TSG 101 exemplify her commitment to advancing medical science. Her work not only enhances our understanding of ovarian cancer but also opens new avenues for diagnosis and treatment.